Securities Class Action Lawsuits Filed Against Chemours, Amylyx, and Agilon

Investors allege failure to disclose material information, leading to significant financial losses.

Investors have until May 20, 2024, to file lead plaintiff applications in a securities class action lawsuit against The Chemours Company for alleged failure to disclose material information.
Amylyx Pharmaceuticals faces a securities class action lawsuit for allegedly overstating the commercial prospects of its ALS treatment, RELYVRIO, and misleading investors about its financial statements.
Agilon Health is accused of failing to disclose material information, leading to a significant revision of its 2023 profit forecasts and a sharp decline in its share price.
The lawsuits are being led by Kahn Swick & Foti, LLC, a firm specializing in securities litigation, with former Louisiana Attorney General Charles C. Foti, Jr. as a partner.
These cases highlight ongoing concerns regarding corporate transparency and the potential impact on investors.